SCHEMBL26042096

SCHEMBL26042096

CC(C)(C)[Si](C)(C)O[C@]1(C)C[C@H](n2cnc3cccc(C(F)F)c32)C1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KRAS P01116 1/20 0.30
SOS1 Q07889 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506993 1.00 KRAS (0.30) KRASSOS1
SCHEMBL25315300 1.00 KRAS (0.30) KRASSOS1
SCHEMBL30506769 0.84 PRPS1 (0.30)
SCHEMBL25315918 0.84 PRPS1 (0.30)
SCHEMBL26042063 0.84 PRPS1 (0.30)
SCHEMBL26042097 0.83
SCHEMBL25316417 0.83
SCHEMBL30506849 0.83
SCHEMBL25924497 0.81 KRAS (0.34) KRASSOS1
SCHEMBL25315239 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR KRAS 4358/4885SOS1 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.